applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of General Medical Sciences Special Emphasis Panel, NIGMS Special Emphasis Panel MORE–4 IN.

**Date:** March 23, 2011.

**Time:** 8:30 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

**Contact Person:** Mona R. Trempe, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN12, Bethesda, MD 20892. 301–594–3998. trempemo@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862.Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, SpecialMinority Initiatives, National Institutes of Health, HHS)

Dated: February 17, 2011.

Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–4187 Filed 2–23–11; 8:45 am]  
BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of General Medical Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of General Medical Sciences Special Emphasis Panel; Genetics and Cell Biology.

**Date:** March 21–22, 2011.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

**Contact Person:** Arthur L. Zachary, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, Natcher Building, Room 3AN–12, Bethesda, MD 20892, 301–594–2886, zacharyar@nigms.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862.Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, SpecialMinority Initiatives, National Institutes of Health, HHS)

Dated: February 17, 2011.

Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–4186 Filed 2–23–11; 8:45 am]  
BILLING CODE 4140–01–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Medicinal Chemistry.

**Date:** February 28, 2011.

**Time:** 1 p.m. to 5 p.m.

**Agenda:** To review and evaluate contract proposals.

**Place:** National Institute of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call)

**Contact Person:** Phillip F. Wiethorn, Scientific Review Officer, DHHS/NIH/ NINDS/DER/SRB, 6001 Executive Boulevard; MSC 9529. Neuroscience Center; Room 3203, Bethesda, MD 20892–9529, 301–496–5368, Wiethornp@ninds.nih.gov.

Dated: April 13, 2011.

**Time:** 8:30 a.m.–4:30 p.m.

**Agenda:** To evaluate the NCI Experimental Therapeutics Program Portfolio.

**Place:** Marriott North Conference Center, 5701 Marriott Road, Rockville, MD 20852.

**Contact Person:** Dr. Barbara Mroczykowska, Executive Secretary, NCI Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892. 301–496–4291, mroczkowskia@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 17, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–4184 Filed 2–23–11; 8:45 am]  
BILLING CODE 4140–01–P
This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: February 17, 2011.

Jennifer S. Spaeth,  
Director, Office of Federal Advisory Committee Policy.